Pfizer Japan Reports Findings in Neurogenic Bladder (Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database): Neurogenic Bladder

2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Neurogenic Bladder is the subject of a report. According to news reporting out of Tokyo, Japan, by NewsRx editors, research stated, “Data on the long-term management of neurogenic bladder (NGB) are scarce. We evaluated the current status of NGB management in Japanese children over 24-month follow-up using the JMDC database.”

Our news journalists obtained a quote from the research from Pfizer Japan, “In this descriptive, observational, retrospective cohort study, patients ( 17 years) with NGB were included. Patient characteristics and their management status were investigated. A multivariate analysis evaluating the potential risk factors for the development of urinary tract infection (UTI) was performed. The diagnosis of spina bifida, demographics, baseline comorbidities, and early use of clean intermittent catheterization (CIC) and/or overactive bladder (OAB) drugs were used as independent variables. Of 883 eligible children, 39.3% had spina bifida. Over 12/24-month post-index periods, renal urinary tract ultrasound and urinalysis were performed at least once in > 35%/ > 45% patients, respectively, while specific tests (urodynamics, cystourethrography, scintigraphy) were performed in substantially fewer (< 11%/ < 13%) patients. Over 24 months, 21.5% patients used OAB medications (mostly anticholinergics) and 10.8% underwent CIC, alone or with medications; 1.2% patients underwent surgery. Lower UTI (23.3%), urinary incontinence (9.7%), and hydronephrosis (7.0%) were the most common incident complications. Multivariate analysis evaluating risk factors for UTI showed significantly higher odds ratios with point estimates of 2 for CIC (5.70), presence of spina bifida (2.86), and constipation (2.07). Overall, urodynamic assessments were inadequately performed. Patients with use of CIC and/or having spina bifida and constipation had a higher risk of UTI, suggesting the need for careful follow-up.”

According to the news editors, the research concluded: “More guideline-compliant and diligent patient management is necessary in Japanese children with NGB.”

This research has been peer-reviewed.

For more information on this research see: Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database. Advances in Therapy, 2023. Advances in Therapy can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Advances in Therapy - http://www.springerlink.com/content/0741-238x/)

Our news journalists report that additional information may be obtained by contacting Naoko Izumi, Internal Medicine and Hospital Medical Affairs, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan. Additional authors for this research include Takeya Kitta and Takahiko Mitsui.

Publisher contact information for the journal Advances in Therapy is: Springer, One New York Plaza, Suite 4600, New York, Ny, United States.

(Our reports deliver fact-based news of research and discoveries from around the world.)